The Hormonal Differential: A Mental Health Provider's Guide to Perimenopause

She's 43, maybe 46, sometimes 39. She's getting more and more anxious and can’t point to an obvious reason why. The depression is there, but it feels heavier this time and less responsive to the things that used to move the needle. She's not sleeping and her joints are aching. All this and yet her doctor says her labs and imaging are normal.

Sound like one of your clients? Perimenopause may be a contributing factor — or even the primary cause — of all of these symptoms.

As a therapist, you’re not going to prescribe medication to treat perimenopause, but you can play a critical role in helping women recognize how this hormonal transition impacts their mental as well as their physical health.

In fact, you may be one of the few health care providers who can help her understand her experience and get the care she needs.

Doctors regularly misdiagnose women in perimenopause

On paper, the symptoms of perimenopause look almost identical to the symptoms of generalized anxiety disorder, major depressive episode, fibromyalgia, and somatization (Maki et al., 2019).

With hormonal factors missing from the differential, providers continue to overlook the effects of perimenopause. As a result, if a client in her early-to-mid 40s presents to a primary care provider with disrupted sleep, fatigue, irritability, low mood, and brain fog, she will mostly likely leave that provider's office with an SSRI or SNRI.

• Women ages 45-54 in the menopausal transition have rates of anxiety and depressive disorders nearly double those of men the same age.
• SSRIs and SNRIs are the most prescribed medications in this group, at a significantly higher proportion than in men with the same diagnoses (Alsugeir et al., 2024).

While women are are being heavily medicated for mood, they continue to be chronically undertreated hormonally.

• Menopausal Hormone Therapy (MHT) among U.S. postmenopausal women dropped from 26.9% in 1999 to just 4.7% by 2020, with lower uptake among Hispanic and non-Hispanic Black women compared to white women (Yang & Toriola, 2024).

Thankfully, MHT is now becoming more accessible through online clinics like Midi Health, Evernow, Alloy, and Elektra Health, but we still have far to go before appropriate hormonal treatment is accessible to all.

As a mental health clinician, you are often the first sustained professional relationship a perimenopausal woman has where someone is actually listening over time.

That makes assessment your most powerful tool: not just the intake session, but across months of sessions, as the hormonal story becomes clearer and the layers of a whole-system transition reveal themselves in the room.

The impact of perimenopause on neurological function

Perimenopause is a years-long hormonal transition (averaging 4 to 8 years) that typically begins in the early-to-mid 40s, well before the final menstrual period (Wegrzynowicz et al., 2025). It begins with menstrual irregularity and ends after 12 consecutive months without a cycle, the point that retroactively marks menopause itself (Yang et al., 2024).

The defining feature of perimenopause is not low estrogen, but fluctuating estrogen. Estrogen doesn't simply decline, it rises and falls erratically (Harvard Health, 2022). Documentation actually shows increases in estradiol during this period (Grub et al., 2021).

The hormonal peaks and crashes of perimenopause destabilize every system where estrogen receptors exist: cardiovascular, skeletal, immune, digestive, dermatological, and neurological (Yang et al., 2024).

When estrogen fluctuates, the brain is destabilized — changes are seen in the brain structure, connectivity, energy metabolism, and neurotransmitter function.

Many of the complaints that bring women to mental health treatment during perimenopause are, in origin, neurological (Mosconi et al., 2024).

Pain and mood are deeply interconnected

In October 2024, researchers formally named and characterized the Musculoskeletal Syndrome of Menopause (MSM), a condition that had been clinically present for decades without a diagnostic label (Wright et al., 2024). As ovarian estrogen declines, the musculoskeletal system loses a critical regulatory signal. The results: widespread joint pain, accelerated muscle and strength loss, increased tendon vulnerability, cartilage degradation, and osteoarthritis progression.

• Up to 71% of perimenopausal women experience these symptoms.
• Up to 25% will be disabled by them through the transition (Wright et al., 2024).

Yet imaging is frequently clear, showing no fractures, tears, or structural findings.

For mental health providers, this is important to be aware of because mood disruption and musculoskeletal pain are not two separate presenting problems. They share a catalyst and they amplify each other.

• The prevalence of depression and anxiety among adults with chronic pain is approximately 40%, significantly higher than in clinical and nonclinical comparison groups (Aaron et al., 2025).

This relationship is bidirectional; chronic pain contributes to the onset and worsening of mood disorders, while anxiety is associated with lower pain thresholds and heightened pain sensitivity, and depression produces altered pain processing including increased pain intensity (Salas-González et al., 2025).

When you see anxiety in a client, check whether there's pain behind it. When there's pain, check the full mood picture.

One more clinical overlap worth highlighting: fibromyalgia and perimenopausal musculoskeletal conditions share such significant clinical features that the two are frequently confused, with the hormonal component consistently underweighted in the differential (Vidal-Neira et al., 2024). If fibromyalgia has already been diagnosed, ask when it appeared in relation to reproductive history as that timing may matter.

Consider your client’s allostatic load

Most clinicians know homeostasis, the balanced internal environment. Few are thinking clinically about allostasis, stability through change.

Chronic stress and high allostatic load are among the strongest risk factors for mood disorders during perimenopause, independent of hormonal levels alone (McElhany et al., 2024).

The woman juggling active parenting, demanding work, and a body in chronic pain in an unstable world is showing a measurable physiological burden, the point where she's overloaded and her body is not coping. She must be treated accordingly.

What to add to your intake

Standard biopsychosocial intake forms were not designed with perimenopausal presentation in mind. Most ask about mood history, trauma, substance use, and social support. Essentially none ask about reproductive stage, menstrual changes, or hormonal history.

This gap creates the conditions where a woman in perimenopause gets treated for what her symptoms look like rather than what's driving them.

Here's are 5 things to add to your intake for women in this age group:

1. Reproductive and hormonal history

When did her cycle start to shift? Are cycles irregular, shorter, longer, or absent for stretches? Has she had prior episodes of PMS, PMDD, or postpartum depression? Perimenopausal mood vulnerability is strongly predicted by prior mood sensitivity to hormonal shifts (Maki et al., 2019); women with that history are at significantly elevated risk.

If none of this has been asked before, it hasn't been assessed and we might be missing something big.

2. Current symptom inventory

Don't limit the exploration to mood or the presenting complaint. Ask about sleep quality, nighttime awakenings, whether she wakes hot. Ask about joint pain, morning stiffness, changes in physical tolerance. Ask about cognitive changes (brain fog, word-finding difficulty, lapses in concentration). Ask about fatigue patterns, especially whether fatigue tracks the cycle. Ask about skin and hair changes. Most clients will not volunteer this information without being asked, and many assume these symptoms are stress-related or early signs of something more serious. The more of these that co-occur, the more hormones are likely at play.

3. Hormonal and laboratory history

Has she had labs done? Do you know what was tested and what wasn't? A few important areas to explore:

• A TSH result in the "normal" range does not rule out subclinical thyroid dysfunction - Free T3, free T4, and TPO antibodies tell a more complete story (Mintziori et al., 2024). Subclinical hypothyroidism produces symptoms that overlap substantially with perimenopausal depression: fatigue, cognitive impairment, mood lability, and sleep disturbance (Lang et al., 2025).
• Ask whether anyone has looked at estradiol, FSH, or progesterone and at what point in the cycle those were drawn; timing can change results.
• Any nutritional deficiencies? B6 deficiency links to cognitive decline and mood disruption; B12 deficiency connects to depression, cognitive impairment, and dementia risk; Vitamin D deficiency associates with mood disorders, immune dysregulation, bone loss, and fatigue; iron deficiency connects to fatigue, cognitive impairment, and mood disruption (which is particularly relevant during perimenopause when irregular cycles can accelerate iron loss before periods cease); and Omega-3 fatty acids link to vasomotor symptom management, mood regulation, and sleep quality (Wylenzek, 2024).

4. Medication and treatment history

Has she recently been prescribed SSRIs or SNRIs? Partial response to antidepressants is clinically meaningful. Mood symptoms during perimenopause may not respond adequately to antidepressants alone. Integration of transdermal estradiol into treatment plans has been shown to produce substantial mood improvement that sequential antidepressant trials alone did not achieve (Mogallapu et al., 2025).

5. Psychosocial amplifiers

Work demands, caregiving load, relationship stress, financial stress, and sociopolitical burden are real contributors to allostatic load, independent of hormonal levels (McElhany et al., 2024). These aren't explanations for mood dysregulation, but rather factors that compound an already destabilized neurobiological picture. Where your client lives, what she earns, and her racial background all shape whether treatment options are available to her. Before you recommend a referral pathway or a treatment option, ask yourself whether she can actually access it.

Ongoing assessment: because hormones fluctuate for years

Your first session is just a foundation; you’ll find that the symptom picture shifts over months and years. What may have been true at intake may not represent what will be happening six months later. Assessment should be continuous. Here are a few meaningful areas to do ongoing assessment with your clients:

When sleep disruption appears or worsens

Don't immediately treat this as a primary sleep disorder. Estrogen and progesterone fluctuations directly affect sleep quality, and vasomotor symptoms are significant contributors to nocturnal awakenings (Troìa et al., 2025). She may be waking up hot, not anxious. Sleep fragmentation caused by hot flashes perpetuates cortisol dysregulation, which further impairs emotional regulation (Lang et al., 2025). There is direct physiological evidence that poorer objective sleep architecture in perimenopausal women (reduced sleep efficiency, increased wakefulness after sleep onset, reduced REM) is significantly associated with higher cortisol levels, while self-reported insomnia alone is not (Sahola et al., 2024).

When pain reports increase

When a client in her 40s begins reporting joint pain, morning stiffness, or musculoskeletal discomfort, don’t just refer her back to her primary care or note somatization. Add MSM to your clinical thinking and document when it appeared in relation to her reproductive history. Pain that flares erratically, rather than progressively, is consistent with hormonal fluctuation. This is the moment to refer to a trained menopause medical provider.

When mood is not responding to treatment as expected

Don’t double down on depressive disorders or use identifiers like “treatment resistant.” Partial antidepressant response in a perimenopausal woman is backed by research; there should not be an increase in dosage or switching medications without re-evaluating the hormonal picture. The guidelines are clear: diagnosis requires identification of the menopausal stage and assessment of co-occurring hormonal symptoms before treatment is determined (Maki et al., 2019). If that step hasn't happened, the assessment cycle isn't complete.

MHT (e.g., transdermal estradiol) appears most effective for mood symptoms that are hormonally driven; symptoms that emerge during perimenopause in women without prior psychiatric history, or that worsen with hormonal fluctuation in ways that track the cycle. It is not established as a standalone treatment for primary depressive or anxiety disorders. What the research supports is that for women whose mood has a significant hormonal driver, antidepressant-only treatment is an incomplete clinical response (Mogallapu et al., 2025; Glynne et al., 2025). Your role is to recognize that distinction and advocate for the complete picture.

When cognitive challenges are a primary complaint

Be mindful of jumping into the neurodevelopment or neurocognitive realm. A systematic review in 2025 found that cognitive concerns, specifically forgetfulness and difficulty concentrating, are among the most frequently reported symptoms in perimenopause.

These symptoms affect daily functioning, work, and relationships. For some clients this means they might be concerned about early-onset dementia or reflect underlying ADHD symptoms (Bangle, 2025); leaving it up to you to help connect the dots.

When a new diagnosis arrives

If a client discloses a new diagnosis (fibromyalgia, anxiety disorder, depressive disorder, sleep disorder) ask when it was given in relation to her reproductive history. If it arrived in her 40s and hormonal assessment wasn't part of the workup, that's worth naming. Don’t dismiss the diagnosis, just make sure the differential is complete.

Your role in integrated care

Mental health providers are not medical menopause specialists, but we are often the most consistent clinical presence in a perimenopausal woman's life during a transition that spans years.

Integrated care means endocrinology, gynecology, primary care, and mental health working from the same hormonal framework (Lang et al., 2025). That integration requires mental health providers who understand enough of the landscape to ask the right questions, make the right referrals, and help clients build language for conversations with their medical teams.

Continuing education and certification pathways exist for clinicians who want to go deeper; take advantage of those!

Mental health treatment should not be a last-resort for perimenopausal women, despite the fact that that’s often how it functions. By the time she reaches your office, she has already been dismissed by multiple providers, prescribed medications that produced partial results at best, and told in one way or another that what she's experiencing isn't fully explainable. The psychological weight of that, the grief of a body that changed without warning, the exhaustion of years of advocacy with no clear answers, the disorientation of a brain that no longer feels reliable… that is the clinical picture.

Processing that experience requires a skilled clinician, a sustained therapeutic relationship, and genuine understanding of the hormonal context driving it. This typically can’t happen in a fifteen-minute medical visit, but it can happen in therapy sessions with a provider who is invested in women’s health.